Emergency Use Authorization for COVID-19 Vaccines and Practical Considerations for the Future

Abstract

An Emergency use authorization (EUA) is a permission granted by the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as revised and upgraded by numerous Federal legislations, which includes the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, accumulated by 21 U.S.C. 360bbb-3, to enable the utilization of medicines before approving. Ensuing regulative specialists expanded the scope of testing to which the medication or treatment has been submitted, as well as the class of drugs qualified for thought. The scope and relevance of EUAs are further governed by actual pioneer, which may change the significance of situations classified as general prosperity crises and within which the FDA might release EUAs Considering the COVID-19 flare-up, the HHS (Health and Human Services) Secretary articulated a general prosperity emergency on February 4, 2020, for the brand-new SARS-CoV-2 disorder these consequences in illness COVID-19. In response to the COVID-19 epidemic, the FDA granted EUAs in 2020 for remdesivir, enhanced blood, Fresenius Propoven 2 percent emulsion (propofol), and bamlanivimab. The FDA cancelled the Emergency use authorization (EUA) that drew in the exploratory monoclonal adjusting proficient medicine Bamlanivimab for use without assistance in the treatment of difficult-to-organize COVID-19 in grown-ups and positive pediatric victims on April 16, 2021.

Keywords

emergency use authorization - FDA - COVID-19 - vaccine - regulation

• References

• 1 Emergency use authorization | FDA. ( n.d. ). Accessed June 18, 2022, at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
• 2 Federal Register: Authorization of emergency use of certain medical devices during COVID-19; availability. ( n.d. ). Accessed June 18, 2022, at: https://www.federalregister.gov/documents/2021/10/28/2021-23501/authorization-of-emergency-use-of-certain-medical-devices-during-covid-19-availability
• 3 Adverse event reporting for medical devices under emergency use authorization (EUA) or discussed in COVID-19-related guidance documents | FDA. ( n.d. ). Accessed June 18, 2022, at: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/adverse-event-reporting-medical-devices-under-emergency-use-authorization-eua-or-discussed-covid-19
• 4 Coronavirus Disease. 2019 (COVID-19) Emergency use authorizations for medical devices | FDA. ( n.d. ). Accessed June 18, 2022, at: https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices
• 5 FDA Guidance. Postmarketing adverse event reporting for medical products and dietary supplements during a pandemic | Loeb & Loeb LLP. ( n.d. ). Accessed June 18, 2022, at: https://www.loeb.com/en/insights/publications/2020/03/postmarketing-adverse-event-reporting-for-medical-products-and-dietary-supplements-during-a-pandemic
• 6 Fda, & Cber. (2022). Contains nonbinding recommendations emergency use authorization for vaccines to prevent COVID-19 guidance for industry preface public comment. Accessed Jan 13, 2023, at: https://asprtracie.hhs.gov/COVID-19
• 7 FAQs. What happens to EUAs when a public health emergency ends? | FDA. ( n.d. ). Accessed June 18, 2022, at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/faqs-what-happens-euas-when-public-health-emergency-ends
• 8 Fda, & Cder. (2020). Guidance for Industry Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic. Accessed Jan 13, 2023, at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
• 9 CDC. ( n.d. ). Accessed June 18, 2022, at: https://www.cdc.gov/coronavirus/2019-ncov/php/pandemic-preparedness-resources.html
• 10 ASPR TRACIE | Healthcare Emergency Preparedness Information Gateway. ( n.d. ). Accessed June 18, 2022, at: https://asprtracie.hhs.gov/
• 11 Medical Countermeasures Dispensing - Emergency Use Authorization and the Postal Model- NCBI Bookshelf. ( n.d. ). Accessed June 18, 2022, at: https://www.ncbi.nlm.nih.gov/books/NBK53122/
• 12 Yu A. ( n.d. ). An analysis of the COVID pandemic emergency use authorization (EUA) and future regulatory strategy considerations. Center of Excellence in Regulatory Science and Innovation; 2021
• 13 CRS INSIGHT Prepared for Members and Committees of Congress HHS Announcement on FDA Premarket Review of laboratory-developed Tests (LDTs). (2020). Accessed Jan 13, 2023, at: https://crsreports.congress.gov
• 14 FDA grants EUA to Lilly's Covid-19 antibody therapy for pediatric use. ( n.d. ). Accessed June 18, 2022, at: https://www.pharmaceutical-technology.com/news/fda-lilly-antibody-paediatric-use/
• 15 Contains Nonbinding Recommendations Preface Public Comment. ( n.d. ). Accessed June 18, 2022, at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/137926/download
• 16 Mishra A, Gowrav MP, Balamuralidhara V, Reddy KS. Health in digital world: a regulatory overview in the United States. J Pharm Res Int 2021; 33 (43B): 438-450
• 17 Navigating The FDA's Emergency Use Authorization Process. ( n.d. ). Accessed June 29, 2022, at: https://www.outsourcedpharma.com/doc/navigating-the-fda-s-emergency-use-authorization-process-0001